Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Provectus Signs LOI for Cancer Drug with Boehringer Ingelheim China

publication date: Jul 2, 2015
Provectus Biopharma, a clinical stage oncology pharma headquartered in Tennessee, has signed an LOI with Boehringer Ingelheim (China) Investment Co. The LOI proposes that Boehringer will support Provectus' efforts to register PV-10, the company's lead cancer molecule, in China. In return, Boehringer will have first priority to collaborate in Provectus' China commercialization of PV-10. One year ago, Provectus signed an LOI with Sinopharm for China rights to PV-10. The agreement, which has been extended several times, will expire in two weeks. More details....

Stock Symbol: (NYSE: PVCT)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here